Miller, Robert E <br/><br/>
Receptor activator of NF-kappa B ligand inhibition suppresses bone resorption and hypercalcemia but does not affect host immune responses to influenza infection.  [electronic resource] 

 -  Journal of immunology (Baltimore, Md. : 1950)  Jul 2007 
 - 266-74 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0022-1767 
<br/><br/><label>Standard No.: </label>10.4049/jimmunol.179.1.266  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Bone Resorption--immunology<br/>Diphosphonates--administration & dosage<br/>Disease Models, Animal<br/>Dose-Response Relationship, Immunologic<br/>Female<br/>Hydroxycholecalciferols--toxicity<br/>Hypercalcemia--immunology<br/>Imidazoles--administration & dosage<br/>Immunity, Innate<br/>Immunoglobulin G--administration & dosage<br/>Influenza A Virus, H3N2 Subtype--immunology<br/>Longitudinal Studies<br/>Male<br/>Mice<br/>Mice, Inbred C57BL<br/>Orthomyxoviridae Infections--immunology<br/>Osteoprotegerin--administration & dosage<br/>RANK Ligand--antagonists & inhibitors<br/>Receptor Activator of Nuclear Factor-kappa B--antagonists & inhibitors<br/>Recombinant Fusion Proteins--administration & dosage<br/>Zoledronic Acid